- Home
- RIGL vs LE Comparison
RIGL vs LE Comparison
Compare RIGL & LE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | LE |
|---|---|---|
| Founded | 1996 | 1963 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 359.4M |
| IPO Year | 2000 | 1994 |
Fundamental Metrics
Financial Performance| Metric | RIGL | LE |
|---|---|---|
| Price | $30.36 | $11.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $45.67 | $32.50 |
| AVG Volume (30 Days) | ★ 407.1K | 206.2K |
| Earning Date | 05-05-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 0.44 | 0.18 |
| Revenue | $294,282,000.00 | ★ $1,162,769,000.00 |
| Revenue This Year | N/A | $5.53 |
| Revenue Next Year | $12.75 | $2.48 |
| P/E Ratio | $68.14 | ★ $65.50 |
| Revenue Growth | ★ 64.15 | 0.72 |
| 52 Week Low | $18.14 | $7.65 |
| 52 Week High | $52.24 | $20.04 |
Technical Indicators
Market Signals| Indicator | RIGL | LE |
|---|---|---|
| Relative Strength Index (RSI) | 55.66 | 51.88 |
| Support Level | $27.98 | $10.09 |
| Resistance Level | $32.17 | $11.82 |
| Average True Range (ATR) | 1.69 | 0.60 |
| MACD | 0.17 | 0.16 |
| Stochastic Oscillator | 64.95 | 61.85 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About LE Lands' End Inc.
Lands' End Inc is a United States-based digital retailer of solution-based apparel, swimwear, outerwear, accessories, footwear, home products, and uniforms. It offers products online at the website (www.landsend.com), through third-party distribution channels, its own company-operated stores, and third-party license agreements. Lands' End also offers products to businesses and schools, for their employees and students, through the Outfitters distribution channel. The company's operating segments consist of: U.S. eCommerce, Europe eCommerce, Outfitters, Third Party, Licensing, and Retail. The majority of its revenue is generated from the U.S. eCommerce segment. Geographically, Lands' End derives maximum revenue from the United States, and the rest from Europe and other markets.